Ketamine Addiction

Understanding ketamine pharmacology, dependence, dissociation, urinary tract harm, and evidence-based residential treatment at Phuket Island Rehab.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Ketamine is an NMDA receptor antagonist developed as a dissociative anaesthetic in the 1960s and now used clinically for anaesthesia, severe pain, and treatment-resistant depression. It is not an opioid. It is also not a benign drug. Recreational and self-administered ketamine carries a real addiction profile, a distinctive pattern of urinary tract damage at high cumulative doses, and a documented risk of severe psychiatric crisis when used to escape rather than to treat. The recent boom in unsupervised online ketamine clinics has produced a new cohort of patients who began with a clinical indication and ended up in compulsive use. At Phuket Island Rehab, our residential programme addresses both the underlying mood disorder and the pattern of dissociative misuse that often hides behind it.

What is ketamine?

Ketamine is a drug, a synthetic dissociative anaesthetic, first developed in 1962 and approved by the U.S. Food and Drug Administration in 1970 for use in human surgical anaesthesia. Ketamine is a dissociative anesthetic at clinical doses and a club drug or party drug at recreational doses. It became widely used in emergency medicine and battlefield trauma care because, unlike most anaesthetics, it preserves breathing and blood pressure at clinical doses. In the 1990s and 2000s, ketamine became a recreational drug, sold as Special K or simply K, snorted in powder form at parties and dance events; it was also a frequent target of veterinary medicine diversion. In 2019, the U.S. Food and Drug Administration approved a derivative, esketamine nasal spray under the brand name Spravato, for treatment-resistant depression. Generic intravenous and intramuscular ketamine has since been used widely off-label for the same indication, with ketamine therapy sessions delivered in clinics for pain relief and major depressive disorder. Ketamine has also become a recognised cause of substance use disorder under the broader category of recreational drug use, with clear health effects on the bladder, brain, and mental health. In the United Kingdom ketamine is a Class B drug.

Ketamine has three lives that overlap in current practice. It is an anaesthetic, used in operating rooms and ambulances worldwide. It is a recreational dissociative, used illicitly for its perceptual and out-of-body effects. And it is a fast-acting antidepressant, increasingly delivered through online clinics that mail oral or intranasal ketamine to patients with little supervision. These three uses involve the same drug and overlap in unpredictable ways. A patient who began as a depression patient can drift into recreational use. A recreational user can develop urological complications that present years before they recognise a pattern.

The street and clinical names matter for recognition. Ketamine is sold as crystals, powder, pressed tablets, vials of intravenous solution, intranasal spray, and oral troches. Slang names include K, Special K, Ket, Kit Kat, Vitamin K, Cat Valium, and Super K. Many recreational users do not know whether their supply is racemic ketamine, S-ketamine, or contaminated with other substances.

Is ketamine an opioid?

Ketamine is not an opioid, and this is a point of frequent confusion. Opioids act at the mu, kappa, and delta opioid receptors. Ketamine acts primarily at the N-methyl-D-aspartate receptor, known as the NMDA receptor, which is one of the brain’s main glutamate receptors. NMDA receptor antagonism reduces the brain’s excitatory signalling in a way that produces dissociation: a sense of detachment from body and surroundings, distorted perception of time and space, and at higher doses the so-called K-hole, a profound, often distressing dissociative state.

Ketamine does have some weak activity at opioid receptors, and there has been ongoing research into whether opioid receptor activation contributes to its antidepressant effect. A 2018 study published in the American Journal of Psychiatry suggested that pre-treatment with naltrexone, an opioid antagonist, blunted ketamine’s antidepressant response, which raised concern that the antidepressant effect is at least partly opioid-mediated. The clinical implication is that ketamine, while not classified as an opioid, sits closer to the opioid system than its anaesthetic mechanism alone would suggest. This is one of several reasons that long-term ketamine treatment requires the same scepticism applied to long-term opioid therapy.

Is ketamine a psychedelic?

Ketamine is often grouped with psychedelics, but the classification is imprecise. True classical psychedelics, psilocybin, lysergic acid diethylamide, mescaline, and N,N-dimethyltryptamine, act primarily through the serotonin 5-HT2A receptor and produce a characteristic profile of visual distortion, emotional intensification, and altered cognition. Ketamine produces dissociation rather than classical psychedelia. The experience is more often described as detachment, depersonalisation, and an out-of-body state than as a serotonergic visual journey.

Functionally, ketamine sits alongside other dissociatives such as phencyclidine, dextromethorphan at high doses, and nitrous oxide. It is sometimes called a dissociative psychedelic to acknowledge the overlap. For clinical purposes, the distinction matters because the harms, the abuse pattern, and the therapeutic mechanism differ from those of classical psychedelics. Ketamine’s antidepressant effect, in particular, appears to involve rapid synaptogenesis and glutamate-mediated plasticity rather than the longer-term mystical-experience mechanisms thought to underlie psilocybin’s therapeutic response.

How ketamine works in the brain

Ketamine binds inside the NMDA receptor ion channel and blocks the flow of calcium and sodium that would otherwise flow when glutamate binds. The result is a rapid suppression of excitatory neurotransmission in cortical and limbic regions. At anaesthetic doses, this produces dissociative anaesthesia, with the patient pharmacologically disconnected from sensation while breathing and circulation continue. At sub-anaesthetic doses, the same mechanism produces dissociation, analgesia, and the rapid antidepressant effect that has driven recent clinical interest.

The antidepressant mechanism appears to involve a paradoxical surge of glutamate release once NMDA receptors are blocked, leading to activation of the AMPA receptor, downstream release of brain-derived neurotrophic factor, and a wave of synaptic remodelling, particularly in the prefrontal cortex. This is the proposed basis for the rapid mood improvement seen in some patients with treatment-resistant depression within hours of a single infusion. The same mechanism is also thought to underlie the dissociative experience itself, and the two effects cannot be cleanly separated.

Ketamine has a short elimination half-life of around two to three hours, and norketamine, its active metabolite, has a half-life of around five hours. The brief pharmacology is part of why ketamine produces an intense but short experience, and part of why patients in compulsive use often re-dose every thirty to sixty minutes throughout an evening.

How ketamine addiction develops

Ketamine produces drug tolerance more quickly and more profoundly than most recreational drugs. Regular ketamine users describe needing two or three times the original dose within weeks to reach the same dissociative state; people who use ketamine daily reach high doses quickly. Physical dependence in the classic opioid sense is not as prominent, but psychological dependence and substance dependence develop readily, and a withdrawal-like cluster of low mood, anhedonia, sleep disturbance, withdrawal symptoms including drug withdrawal-style cravings and a craving cycle emerges in heavy users when they try to stop. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, does not list a separate ketamine use disorder but captures the same pattern under hallucinogen use disorder; ketamine abuse and recreational use of ketamine fit the broader sedative-hypnotic and dissociative substance abuse pattern.

The addiction trajectory typically begins with recreational use at parties or festivals. Tolerance grows, the social context shifts to home use, and the patient begins to dose alone, often daily. At this stage, the drug is no longer about the party experience but about escape: from anxiety, from depression, from a life that feels overwhelming. A separate pathway involves patients who began ketamine therapy for depression and crossed, sometimes with the clinic’s encouragement, from supervised infusions into self-administered oral troches sent through the post. The line between treatment and misuse is genuinely blurred in this group, and our team has seen several patients in this position in the last two years alone.

Signs of ketamine addiction

Recognising a problem with ketamine is often difficult because the drug does not produce the kind of obvious daily intoxication that alcohol or opioids do. The signs are subtler: increasing time spent in dissociative states alone, dose escalation, declining work performance, social withdrawal, urinary symptoms that the patient is reluctant to investigate, and a defensive posture when the drug is questioned. Cognitive complaints, particularly memory difficulty and slowed thinking, are common after months of heavy use and improve only partly after stopping.

Heavy users often inject or snort ketamine and combine it with alcohol, MDMA, cocaine, or benzodiazepines. Mixing ketamine with other depressants intensifies the dissociative experience, and so does the risk. Drug and alcohol problems often coexist. Combining ketamine with alcohol or benzodiazepines magnifies sedation and increases the risk of aspiration during a dissociative episode, including the chance of ketamine overdose. Combining it with cocaine or MDMA stresses the cardiovascular system in ways the dissociation hides. Patients sometimes do not realise they have a serious medical problem until urinary symptoms, abdominal pain, memory loss, or weight loss force the issue. The dose of ketamine and the amount of ketamine relative to body weight matter; the effects of ketamine use vary by route, with snorting and injection producing faster, more intense, and harder-to-control experiences. People who become dependent on ketamine often describe turning to ketamine for emotional regulation, not for the high, and many recognise themselves in descriptions of the agony of ketamine addiction once they begin to seek help and to look for support groups.

Ketamine bladder syndrome and other physical harms

The most distinctive long-term harm of chronic ketamine use is a urological syndrome called ketamine-induced cystitis or ketamine bladder. Heavy users develop urinary frequency, urgency, painful urination, blood in the urine, and reduced bladder capacity, sometimes shrinking to the size of a walnut after several years of use. The mechanism involves direct toxicity of ketamine and its metabolites on the urothelial lining, with chronic inflammation, ulceration, and fibrosis. In severe cases, patients have required surgical reconstruction or cystectomy. The condition was first described in the medical literature in 2007 and is now a recognised diagnosis.

Hepatobiliary injury, in particular cholestasis with raised liver enzymes and abnormal biliary imaging, occurs in some heavy users and resolves slowly after stopping. Cognitive impairment, particularly in working memory and executive function, has been documented in multiple studies of chronic recreational users and improves but does not fully resolve in the months after cessation. Cardiovascular effects include hypertension and tachycardia during use, with rare reports of arrhythmia in patients combining ketamine with other stimulants.

System	Common findings in heavy chronic ketamine use	Reversibility
Urinary tract	Urgency, frequency, dysuria, haematuria, reduced bladder capacity, ketamine cystitis	Partial; early cessation gives best recovery
Hepatobiliary	Raised ALT and ALP, cholestasis, biliary dilatation	Generally good with cessation
Cognitive	Reduced working memory, executive dysfunction, slowed processing	Partial recovery over months
Mental health	Depression, anxiety, depersonalisation, vivid dreams	Variable; sometimes worse than baseline
Cardiovascular	Hypertension, tachycardia in use	Reversible on cessation

Ketamine withdrawal

Ketamine does not produce the classic autonomic withdrawal syndrome of opioids or alcohol. There is no risk of seizures or delirium tremens. What does emerge in the days after stopping heavy use is a cluster of psychological symptoms: low mood, anhedonia, fatigue, vivid disturbed dreams, anxiety, and intense cravings. Sleep is often broken for one to three weeks. A return of the underlying depression that ketamine was suppressing, sometimes worse than before, is common in patients who used ketamine for mood reasons.

The high-risk period is the first month, when cravings are strongest and the patient is left without the dissociative escape they have been relying on. Suicidal ideation can emerge in this phase, particularly in patients who began ketamine for treatment-resistant depression and find themselves both off the medication and unmedicated. Close clinical contact through this phase is essential, and residential support gives the patient the structure to ride out the worst weeks safely.

Treatment at Phuket Island Rehab

Patients arrive at our centre for ketamine treatment from three main entry points. Some are recreational users with several years of escalating use, often presenting with bladder symptoms or relationship breakdown. Some are former depression patients whose at-home ketamine programme has shifted into compulsive use. Some are polysubstance users for whom ketamine is one strand among several. The treatment plan and treatment options look different for each, but the core elements are shared: medical assessment of urinary and hepatic complications, gradual psychological stabilisation, structured therapy addressing the dissociative coping pattern, and re-engagement with what dissociation has been substituting for. Our medically assisted detox, drug rehabilitation pathway, and treatment services for ketamine dependence are designed around the specific physical health effects of ketamine, the mental health disorder dimension of long-term use, and the wellbeing of the patient’s wider life. Treatment for ketamine addiction requires patience: ketamine addiction requires a longer time horizon than many patients expect. Treatment for substance use disorders that include ketamine also addresses the broader pattern of substance use rather than the single drug. Patients struggling with ketamine or struggling with addiction related to ketamine, or someone you know is struggling with daily use, benefit most from inpatient care delivered by a treatment team. Help for ketamine starts with seeking professional help; counselling, talk therapy, and peer support groups all have a role.

Detoxification from ketamine is largely a matter of supportive care. There is no specific pharmacological substitution. Sleep is the main symptomatic target, and we use non-benzodiazepine approaches where possible, given that many patients have used z-drugs and benzodiazepines alongside ketamine. Mood stabilisation in the first weeks may involve adjustment or restart of standard antidepressants, with the explicit understanding that they will take longer to work than the patient has been used to with ketamine.

Therapy is the heart of the work. Most patients have used ketamine for dissociation, and dissociation is a coping strategy for distress that the person has not yet developed alternatives for. The clinical task is partly trauma processing, partly building the tolerance for ordinary emotional experience that dissociative use erodes. Our counsellors use a combination of trauma-focused therapies, mindfulness work, and the slow rebuilding of a life that does not require regular chemical retreat from itself.

Why international clients come to Thailand

Ketamine treatment in many Western countries is now a confusing landscape of telehealth providers, ketamine bars, micro-dosing protocols, and at-home regimens of varying quality. Patients who have got into trouble in this environment often want geographic and operational distance from the clinic that prescribed them, the dealer they have been buying additional supply from, and the social circle that uses with them. Thailand provides that distance without the cost or visibility of equivalent residential care at home.

Privacy is a second factor. Ketamine use, particularly in professional or executive populations, carries a stigma that opioid or alcohol addiction does not, partly because it intersects with mental health treatment in ways that are hard to separate. A confidential residential programme outside the patient’s home country allows full engagement with the issue without the career risk that domestic treatment can carry.

When ketamine use has become more than occasional

Most of the patients we see did not start out to develop a problem with ketamine. They started out to get relief from depression, anxiety, or the kind of chronic low-grade distress that did not have an obvious diagnosis. The drug worked, more or less, until it stopped working and they could not stop using it. Heavy alcohol use is often part of the picture, masked because the patient sees the ketamine as the real issue. Both need to be addressed.

If you have noticed that your use has crept up, that you are dosing alone, that you are losing interest in the parts of life that used to matter, or that you have begun to notice urinary symptoms or memory lapses, these are signals that the pattern has moved past occasional use. They are not a verdict and they do not mean that ketamine has no legitimate place in your treatment. They do mean that a conversation with an addiction specialist, an honest review of the dose and frequency, and a properly supervised pause are reasonable next steps.

Summary

Ketamine is a fast-acting NMDA receptor antagonist with legitimate clinical roles in anaesthesia, severe pain, and treatment-resistant depression. It is also a drug of misuse and, in chronic heavy use, a cause of severe urological and cognitive harm. Tolerance develops rapidly, physical dependence is mild but psychological dependence is strong, and the recent boom in unsupervised at-home prescribing has produced a new and growing cohort of patients in compulsive use. Effective treatment combines medical assessment of physical harms, supportive detox, structured therapy for the dissociative coping pattern, and re-engagement with treatment for the underlying mood disorder that the drug was attempting to silence.

As Dr. Ponlawat Pitsuwan puts it, “The hardest part of treating ketamine misuse is not the drug. It is what the drug has been holding off. Patients who come into recovery have to learn to be present in their own lives again, and that work cannot be done in a dissociative state. Our job is to make the present tolerable enough that they want to stay in it.”

Frequently asked questions

Is ketamine addictive?

Yes. Ketamine produces rapid tolerance, a recognisable pattern of psychological dependence, and a withdrawal-like cluster of low mood, anhedonia, sleep disturbance, and intense cravings when heavy users try to stop. Classic physical dependence is mild compared with opioids, but the behavioural pattern of compulsive use, escalating dose, and use despite consequences is well documented. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, captures this under hallucinogen use disorder.

Is ketamine an opioid?

Ketamine is not classified as an opioid. It acts primarily at the NMDA glutamate receptor rather than at the opioid receptors. It does have weak activity at the mu opioid receptor, and research published in the American Journal of Psychiatry in 2018 suggested that this contributes to its antidepressant effect. The practical implication is that ketamine sits closer to the opioid system than its formal classification suggests, which is one reason long-term use requires careful supervision.

What is a K-hole?

A K-hole is a profound, often distressing dissociative state produced by higher recreational doses of ketamine. Users describe complete loss of contact with body and surroundings, sometimes accompanied by a sense of dying, hallucinations, and disturbing existential experiences. Anaesthetists call the same state dissociative anaesthesia, and in a controlled clinical setting it is the goal. Outside that setting it is unpredictable, frightening, and a frequent reason for emergency presentation, particularly when combined with alcohol or benzodiazepines that increase the risk of vomiting, aspiration, and injury.

What is ketamine bladder?

Ketamine bladder, or ketamine-induced cystitis, is a chronic inflammatory condition of the bladder caused by long-term heavy ketamine use. Patients develop urinary urgency, frequency, painful urination, blood in the urine, and a shrunken bladder capacity. The mechanism involves direct toxicity of ketamine and its metabolites on the bladder lining. Early cessation gives the best chance of recovery; in advanced cases patients have needed surgical reconstruction or removal of the bladder. Any heavy user with urinary symptoms should stop the drug and see a urologist.

How is at-home ketamine therapy different from misuse?

At-home ketamine therapy is often legitimate, when it involves a properly assessed patient, a structured protocol, careful dose limits, and regular psychiatric review. It tips into misuse when doses escalate without clinical justification, when use becomes daily, when patients begin to dose for general distress rather than for the treatment indication, when use is hidden from the prescribing clinician, or when the experience of dissociation itself becomes the goal. The boundary is sometimes hard to see from inside the experience, which is why honest external review matters.

Can you safely stop ketamine without medical help?

Stopping ketamine does not carry the kind of life-threatening withdrawal seen with alcohol or benzodiazepines. There are no seizures, no delirium. What there is, in heavy users, is a psychological withdrawal cluster of low mood, intense cravings, sleep disturbance, and sometimes worsening depression. Patients who began ketamine for treatment-resistant depression are particularly vulnerable to suicidal ideation in the early weeks off the drug. A residential or closely supervised outpatient programme is far safer in this group, and in our experience also far more likely to actually result in sustained abstinence.

Sources

National Institute on Drug Abuse. Hallucinogens drug facts and research reports including ketamine. nida.nih.gov.

U.S. Food and Drug Administration. Esketamine (Spravato) prescribing information and risk evaluation strategy. fda.gov.

Williams NR et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. American Journal of Psychiatry, 2018.

Shahani R et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology, 2007.

National Health Service. Ketamine information and treatment guidance. nhs.uk.

American Society of Ketamine Physicians, Psychotherapists, and Practitioners. Best practice guidelines for clinical use of ketamine. askp.org.

Related reading on this site

• What is ketamine?
• What is ketamin (common misspelling)
• Is ketamine an opioid?
• Is ketamine addictive?
• Is ketamine a psychedelic?
• Ketamine rehab
• Ketamine rehab in Thailand
• Ketamine addiction treatment
• Hallucinogens addiction
• Depression treatment
• Medical detox at Phuket Island Rehab

Ketamine, esketamine, Spravato, S-ketamine, racemic ketamine, norketamine, Special K, Vitamin K, K-hole, club drug, party drug, NMDA receptor, glutamate, AMPA receptor, BDNF, brain-derived neurotrophic factor, dissociative anesthetic, dissociative anaesthetic, anesthesia, anesthetic, ketamine-induced cystitis, ketamine bladder, urothelial toxicity, urinary incontinence, abdominal pain, memory loss, amnesia, cholestatic liver injury, hallucinogen use disorder, substance use disorder, substance dependence, substance abuse, recreational drug use, drug withdrawal, drug rehabilitation, drug tolerance, major depressive disorder, mental disorder, mental health, signs and symptoms, dose (biochemistry), disease, adolescence, DSM-5, treatment-resistant depression, telehealth ketamine, Class B drug, veterinary medicine, polydrug use, alcohol use disorder, alcohol (drug), U.S. Food and Drug Administration, National Institute on Drug Abuse, American Journal of Psychiatry, National Health Service, Phuket Island Rehab.